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The pretreatment neutrophil/lymphocyte ratio (NLR), derived from differential white blood 
cell counts, has been previously associated with poor prognosis in breast cancer. Little 
data exist, however, concerning this association in Black patients, who are known to have 
lower neutrophil counts than other racial groups. We conducted a retrospective cohort 
study of 236 Black and 225 non-Hispanic White breast cancer patients treated at a 
single institution. Neutrophil and lymphocyte counts were obtained from electronic med-
ical records. Univariate and multivariate Cox regression models were used to determine 
hazard ratios (HRs) and 95% confidence intervals (95% CIs) of all-cause mortality and 
breast cancer-specific mortality in relation to pretreatment NLR. Overall, there were no 
associations between an elevated pretreatment NLR (NLR ≥3.7) and all-cause or breast 
cancer-specific mortality. Among patients without metastasis at the time of diagnosis, 
an elevated pretreatment NLR was independently associated with all-cause mortality, 
with a multivariable HR of 2.31 (95% CI: 1.10–4.86). Black patients had significantly 
lower NLR values than White patients, but there was no evidence suggesting racial 
heterogeneity of the prognostic utility of NLR. Pretreatment NLR was an independent 
predictor of all-cause mortality but not breast cancer-specific mortality in non-metastatic 
breast cancer patients.
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inTrODUcTiOn
Breast cancer is the most common cancer in women and is the second leading cause of cancer death 
in women in the United States (1). Tumor stage, grade, and tissue markers, such as hormone receptor 
status and HER2 overexpression, are well-known independent prognostic indicators in breast cancer 
(2–5). In recent years, increasing data suggest that tumor infiltrating lymphocytes (TILs) may also 
Abbreviations: NLR, neutrophil/lymphocyte ratio (the ratio of peripheral blood neutrophils to peripheral blood lymphocytes, 
obtained from the differential counts of a complete blood count performed on venous blood).
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have prognostic value in breast cancer (6, 7). This interaction 
between the tumor and immune system may also extend beyond 
the local tissue environment. Indeed, a systemic inflammatory 
response, determined by elevated circulating levels of C-reactive 
protein and interleukin-6, has been associated with poor overall 
and disease-specific survival among breast cancer patients (8, 9).
The pretreatment neutrophil/lymphocyte ratio (NLR), derived 
from differential white blood cell (WBC) counts, is another 
parameter of systemic inflammation and host immune reaction, 
which is routinely available in the clinical setting. A few studies 
have reported that an elevated pretreatment NLR is associated 
with an increased risk of relapse and worse survival among 
breast cancer patients (10–19). The pretreatment NLR has been 
associated with worse prognosis in a variety of different cancers, 
including colorectal cancer (20), non-small cell lung cancer (21, 
22), renal cell carcinoma (23, 24), gastric cancer (25, 26), naso-
pharyngeal carcinoma (27, 28), hepatocellular carcinoma (29), 
and esophageal cancer (30). Additionally, Chua et  al. reported 
that midtreatment NLR (measured after one cycle of chemo-
therapy) was associated with improved progression-free survival 
(p = 0.012) in colorectal cancer (31).
Blacks are generally known to have lower neutrophil counts 
and similar lymphocyte counts compared to their White coun-
terparts (32). However, little data exist concerning the association 
between the pretreatment NLR and breast cancer prognosis in 
Black patients. We, therefore, examined whether an elevated 
pretreatment NLR is associated with all-cause and breast cancer-
specific mortality in Black and White patients treated at a single 
institution.
MaTerials anD MeThODs
study Design and Data source
Our study was a retrospective review of medical charts of breast 
cancer patients registered in the Tumor Registry at the Georgia 
Regents University (GRU) Cancer Center. Out of 1,208 patients 
registered between April 2001 and August 2013, we identified 464 
patients who had differential WBC counts determined prior to 
initial treatment and excluded 3 patients who were members of 
racial/ethnic groups other than Black or non-Hispanic White. The 
total WBC count and the percentage of each neutrophil and lym-
phocyte were extracted from electronic medical records (EMR) 
to estimate the absolute neutrophil and lymphocyte counts. The 
NLR was then calculated by dividing the estimated neutrophil 
count by the estimated lymphocyte count. Also extracted from 
the EMR was information on a patient’s height and weight at the 
time of diagnosis or at a proximate time possible to compute body 
mass index (BMI, kilogram per square meter).
Other major information used in this study was obtained 
from the hospital tumor registry, which abstracts and codes the 
data on all patients diagnosed and/or treated for cancer at the 
GRU Hospital following the state cancer registry standards. This 
included information on patient characteristics (age at diagnosis, 
race, primary payer at diagnosis, and tobacco use history), tumor 
(date of diagnosis, stage at diagnosis, grade, and hormone recep-
tor status), treatment course (surgery, radiation, chemotherapy, 
and hormone therapy), and follow-up data (date of last contact, 
date and type of recurrence, and vital status). EMR were further 
searched among patients expired by the follow-up end date 
in order to determine if death was attributed to breast cancer. 
Death was considered a result of breast cancer if (1) “a patient 
was never been free of breast cancer since diagnosis because of 
already metastasized diseases and/or treatment failure/refusal” 
or “a patient was disease-free after initial treatment but had a 
record of disease recurrence” and (2) medical records within 
3  months from the expiration date indicate at least one of the 
following: widespread metastasis into multiple organs; malignant 
pleural effusion; significant disease progression and functional 
decline; or referral to hospice care. The study was approved by 
the Institutional Review Board of GRU. The informed consent 
process and the documentation of consent was waived because 
the study was a retrospective chart review that involved no 
greater than minimal risk and did not collect protected health 
information.
statistical analysis
Our primary endpoint was overall survival. Overall survival was 
calculated from the date of diagnosis to the date of death from 
any causes (censored) or last follow-up (right-censored). A best 
cutoff point for NLR was established by examining hazard ratios 
(HRs), SEs, and p-values for various cutoff points obtained from 
a univariate Cox regression (log-rank test) comparing survival 
curves of individuals above and below each cutoff point (33, 
34). Multivariate Cox regression models were used to determine 
adjusted HRs after controlling for age, stage, grade, and hormone 
receptor status (adjustment model 1); adjustment model 1 plus 
smoking and BMI (adjustment model 2); and all adjustment 1 
and 2 factors plus payer type, receipt of chemotherapy, and receipt 
of radiation therapy (adjustment model 3). A test for linear trend 
between stage and NLR was conducted by using univariate linear 
regression. In addition to an analysis, including all patients, we 
conducted subgroup analyses by race and metastasis status. All 
analyses were performed in R 3.2.
resUlTs
This study included 461 (236 Black and 225 White) patients with 
breast cancer (Table  1). Overall, 122 (65 Black and 57 White) 
patients died during a median follow-up of 5.1 years [interquar-
tile range (IQR): 5.4]. The median age at diagnosis was 57.8 years 
(IQR: 19). The median BMI was 29.5 kg/m2 (IQR: 9.4), and 20% 
of patients were current smokers. A majority of patients (90.1%) 
had some type of health insurance at the time of diagnosis, and 
93% had a surgery as a part of the treatment compared with 51 
and 46% having radiation and chemotherapy, respectively.
Approximately half of the patients had in  situ (N =  81 or 
19%) or stage I (N = 149 or 34%) tumors, followed by 28% of 
patients with stage II, 15% with stage III, and 4% with stage IV. 
The proportion of patients with grade I, II, III, and IV tumors was 
21, 29, 49, and 1%, respectively. The most frequent tumor subtype 
was the subtype positive for both the estrogen receptor (ER) and 
progesterone receptor (PR) (62%). The median counts of WBCs, 
neutrophils, and lymphocytes were 6.7, 4.1, and 2, respectively.
TaBle 1 | Patient and clinical characteristics and their relationship 
with overall survival in a hospital-based retrospective cohort study 
(2001–2013).
no. (%) Unadjusted hr (95% ci)
age
<50 129 (28.0%) 1.22 (0.79, 1.88)
50–64 186 (40.3%) 1. (Ref.)
≥65 146 (31.7%) 1.29 (0.84, 1.99)
Missing 0 –
race
Black 236 (51.2%) 1.08 (0.76, 1.54)
Non-Hispanic White 225 (48.8%) 1. (Ref.)
BMi
<25 108 (25.2%) 1. (Ref.)
25–29.9 121 (28.2%) 0.53 (0.31, 0.92)
30–34.9 102 (23.8%) 0.91 (0.54, 1.52)
≥35 98 (22.8%) 0.87 (0.51, 1.48)
Missing 32 –
smoking
Never 254 (61.1%) 1. (Ref.)
Former 78 (18.8%) 1.14 (0.69, 1.90)
Current 84 (20.2%) 1.42 (0.90, 2.23)
Missing 45 –
Type of medical insurance
Private/Medicare/uniformed 337 (74.2%) 1. (Ref.)
Medicaid 73 (16.1%) 2.22 (1.46, 3.38)
None 44 (9.7%) 1.64 (0.95, 2.83)
Missing 7 –
stage
0 and I 213 (52.4%) 1. (Ref.)
II 114 (28.1%) 2.54 (1.44, 4.50)
III 62 (15.3%) 4.68 (2.61, 8.38)
IV 17 (4.2%) 12.60 (6.23, 25.30)
Missing 7 0
grade
I 84 (21.2%) 1. (Ref.)
II 115 (29.0%) 1.67 (0.85, 3.27)




ER+, PR+ 244 (61.9%) 1. (Ref.)
ER+, PR− 46 (11.7%)
ER−, PR+ 9 (2.328%)
ER−, PR− 95 (24.1%) 2.18 (1.45, 3.28)
Missing 67 –
Type of therapy
Surgery 427/461 (92.6) 0.13 (0.08, 0.20)
Radiation therapy 232/452 (51.3) 0.63 (0.44, 0.91)
Chemotherapy 210/458 (45.9) 1.77 (1.22, 2.56)
Systemic hormone therapy 234/445 (52.6) 0.54 (0.37, 0.78)
Median (interquartile range)
Total WBC 6.7 ± 2.9 0.98 (0.91, 1.05)
Neutrophil count 4.1 ± 2.2 1.02 (0.94, 1.11)
Lymphocyte count 2.0 ± 0.8 0.74 (0.57, 0.95)
FigUre 1 | Median nlr levels by tumor stage, according to race. Test 
for linear trend was done with univariate linear regression and tests by stage 
were done using the Mann–Whitney test.
3
Rimando et al. Neutrophil–Lymphocyte Ratio in Breast Cancer
Frontiers in Oncology | www.frontiersin.org March 2016 | Volume 6 | Article 81
As expected, the HRs of all-cause mortality increased in 
relation to advanced tumor stage [HR for stage IV versus stage 
0 or I: 12.60, 95% confidence interval (95% CI): 6.23–25.30], 
higher grade (HR for grade III/IV versus grade I: 2.18, 95% CI: 
1.18–4.04), and negative hormone receptor status (HR for ER− 
and PR− versus ER+ or PR+: 2.18, 95% CI: 1.45–3.28). Having 
Medicaid as a primary payer source and receiving chemotherapy 
were also associated with elevated risk of all-cause mortality in 
univariate analyses, but other patient factors, such as age, race, 
BMI, and smoking history, were not associated with overall 
survival. No relationship was observed with WBC, neutrophil, 
or lymphocyte counts.
Black patients had lower NLR values compared with White 
patients, with a median NLR (IQR) of 1.77 (1.14) for Black patients 
and 2.28 (1.25) for White patients. This racial difference in NLR 
remained even when stratified by tumor stage [all p-values <0.001 
except for the stage IV (p = 0.096)] (Figure 1). Interestingly, a 
positive association between tumor stage and the NLR value 
was evident only among White patients (p-value for a linear 
trend =  0.02) and was not observed in Black patients (p-value 
for a linear trend =  0.27). Due to differences in NLR between 
Black and White patients, we calculated an optimal NLR cutoff 
point that would significantly predict all-cause mortality in each 
racial group and in the combined patient population (Figure 2; 
Table 2). A high HR with the lowest p-value was observed at the 
NLR cutoff value of 3.6 among Black patients and at 3.8 among 
White patients. However, there was only little difference in the 
HRs and the associated p-values in a range of NLR cutoff values 
between 3.6 and 3.8 in both racial groups. We thus used an overall 
optimal cutoff point of 3.7 in subsequent analyses.
We further explored other patient parameters associated with 
the pretreatment NLR value (Table 3). Patients in the high NLR 
group defined as NLR ≥3.7 had higher WBC and neutrophil 
counts but lower lymphocyte counts compared to those in the 
low NLR group (NLR <3.7) (all p-values <0.001). There were 
more stage IV (17 versus 8%) and high-grade tumors (67 versus 
FigUre 2 | The hazard ratio and p-value for all-cause mortality in patients above or equal versus below the corresponding nlr cutoff 
displayed on x-axis.
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47%) in the high NLR group than in the low NLR group, but 
the differences were not statistically significant. Other patient 
parameters, such as age, BMI, and smoking status, were also 
not significantly associated with the NLR groups. Using 3.7 as a 
cutoff point to define the high NLR group, there were fewer Black 
patients in the high NLR group compared with White patients, 
but the difference was only borderline significant (39 versus 61%, 
p = 0.07).
A total of 11% of breast cancer patients (8.5% of Black and 
13.8% of White) had a pretreatment value of NLR ≥3.7 and was 
defined to have an elevated pretreatment NLR. In the univariate, 
unadjusted analysis, high NLR was associated with increased 
all-cause mortality (HR = 2.38, 95% CI: 1.52–3.72; p < 0.001 by 
the log-rank test) (Table 4; Figure 3). The univariate HR associ-
ated with the high NLR was similar between Black (HR = 2.55, 
95% CI: 1.30–5.00) and White (HR = 2.37, 95% CI: 1.29–4.34) 
patients. After adjustment for age, stage, grade, and combined 
ER/PR receptor status, however, the high NLR was no longer 
significantly associated with all-cause mortality (HR = 1.47, 95% 
CI: 0.80–2.70).
TaBle 2 | race-specific and overall hrs and p-values for all-cause mortality across different nlr cutoff points.
nlr cutoff Black White all
hr se p hr se p hr se p
2.0 1.398 0.250 0.180 1.392 0.290 0.254 1.333 0.183 0.116
2.1 1.467 0.253 0.130 1.420 0.285 0.219 1.367 0.182 0.085
2.2 1.500 0.257 0.115 1.471 0.275 0.160 1.416 0.181 0.055
2.3 1.374 0.265 0.231 1.650 0.272 0.066 1.446 0.182 0.043
2.4 1.522 0.269 0.119 1.777 0.270 0.033 1.583 0.182 0.012
2.5 1.397 0.283 0.237 2.137 0.271 0.005 1.666 0.184 0.005
2.6 1.340 0.295 0.320 2.368 0.269 0.001 1.737 0.185 0.003
2.7 1.366 0.310 0.315 2.416 0.267 0.001 1.780 0.188 0.002
2.8 1.544 0.310 0.161 2.338 0.266 0.001 1.850 0.191 0.001
2.9 1.654 0.310 0.105 2.126 0.267 0.005 1.815 0.194 0.002
3.0 1.752 0.310 0.071 2.246 0.269 0.003 1.931 0.197 0.001
3.1 1.914 0.310 0.036 1.886 0.282 0.024 1.854 0.206 0.003
3.2 1.914 0.310 0.036 1.759 0.290 0.052 1.804 0.210 0.005
3.3 2.294 0.311 0.007 1.814 0.303 0.049 1.987 0.216 0.001
3.4 2.439 0.321 0.005 2.097 0.303 0.014 2.204 0.218 >0.001
3.5 2.583 0.332 0.004 2.118 0.303 0.013 2.245 0.221 >0.001
3.6 2.797 0.332 0.002 2.096 0.309 0.017 2.314 0.225 >0.001
3.7 2.548 0.344 0.007 2.369 0.309 0.005 2.381 0.228 >0.001
3.8 2.363 0.360 0.017 2.693 0.309 0.001 2.478 0.232 >0.001
3.9 2.478 0.378 0.016 2.162 0.337 0.022 2.238 0.250 0.001
4.0 2.478 0.378 0.016 2.072 0.350 0.037 2.210 0.256 0.002
4.1 2.636 0.378 0.010 2.004 0.365 0.057 2.225 0.262 0.002
4.2 2.957 0.378 0.004 1.959 0.383 0.079 2.338 0.269 0.002
4.3 3.168 0.401 0.004 1.873 0.405 0.121 2.320 0.284 0.003
4.4 3.168 0.401 0.004 1.873 0.405 0.121 2.320 0.284 0.003
4.5 2.703 0.429 0.020 1.600 0.433 0.278 1.981 0.304 0.020
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Compared with patients without metastasis, patients with 
metastatic breast cancer are more likely to have overtly altered 
inflammatory states and tumor responses (35, 36) and shorter 
survival largely attributed to breast cancer. We, thus, analyzed the 
relationship between NLR and all-cause mortality, after exclud-
ing stage IV breast cancer patients (Table  3). The unadjusted 
HRs associated with high NLR were 2.43 (95% CI: 1.36–4.35) 
in all patients and 2.78 (95% CI: 1.16–6.64) and 2.28 (95% CI: 
1.03–5.03) among Black and White patients, respectively. The 
high NLR remained a significant independent prognostic fac-
tor for overall survival among non-metastatic breast cancer 
patients after adjustment for the clinical factors of age, stage, 
grade, and combined ER/PR receptor status (HR =  2.12, 95% 
CI: 1.05–4.29) and additional adjustment for the patient factors 
of BMI and smoking history and the treatment factors of payer 
category, chemotherapy regimen, and radiation therapy regimen 
(HR = 2.27, 95% CI: 1.02–5.08).
Out of 122 patients who died during the study follow-up, 
54 (10 in high NLR group and 44 in low NLR group) deaths 
were determined attributable to breast cancer. High NLR was 
significantly associated with breast cancer-specific mortality 
(unadjusted HR = 2.16, 95 CI: 1.09–4.30) but the association no 
longer remained after adjustment for clinical factors (adjusted 
HR = 1.78, 95% CI: 0.71–4.42) (Table 5). Race and tumor metas-
tasis status did not influence the relationship between the NLR 
and breast cancer-specific mortality.
DiscUssiOn
In a cohort of 461 Black and White patients with breast cancer, 
elevated pretreatment NLR, defined as 3.7 or higher, was not 
significantly associated with all-cause or breast cancer-specific 
mortality after considering patient and clinical factors. By con-
trast, elevation in pretreatment NLR was an independent predic-
tor of all-cause mortality among breast cancer patients without 
metastasis at the time of diagnosis.
Some previous studies have reported that NLR is associated 
with breast cancer-specific mortality. Forget et al. found decreased 
recurrence-free survival in breast cancer patients with elevated 
pretreatment NLR, but multivariate analyses were not conducted 
in that study due to small sample size (15). More recently, Krenn-
Pilko et  al. reported that NLR >3 is an independent predictor 
of poor disease-free survival but not of overall survival in 762 
European female breast cancer patients (37). Pretreatment NLR 
≥2.5 was independently associated with breast cancer-specific 
mortality in two studies of Asian patients with stage I–III breast 
cancer (13, 14). One of the studies also showed that elevated NLR 
was associated with worse disease-specific survival particularly 
among patients with the luminal A subtype breast cancer (13). 
On the other hand, a pretreatment NLR ≥2.5 was not associated 
with the 21-gene recurrence score in a population of 242 ER+ 
breast cancer patients (38). A significant association of pretreat-
ment NLR with both overall and disease-free survival has been 
TaBle 4 | all-cause mortality in relation to high nlr (≥3.7) versus low nlr (<3.7).
Black White combined
Deaths hr 95% ci Deaths hr 95% ci Deaths hr 95% ci
all stages
Unadjusted 65 2.55 (1.30, 5.00) 57 2.37 (1.29, 4.34) 122 2.38 (1.52, 3.72)
Adjustment model 1 44 1.86 (0.78, 4.46) 32 1.04 (0.39, 2.76) 76 1.47 (0.80, 2.70)
Adjustment model 2 35 1.82 (0.66, 5.05) 25 1.76 (0.56, 5.57) 60 1.52 (0.79, 2.91)
Adjustment model 3 35 1.3 (0.43, 3.91) 25 1.49 (0.44, 5.07) 60 1.47 (0.73, 2.96)
excluding stage iV
Unadjusted 40 2.78 (1.16, 6.64) 35 2.28 (1.03, 5.03) 75 2.43 (1.36, 4.35)
Adjustment model 1 34 2.53 (0.97, 6.62) 23 1.68 (0.51, 5.53) 57 2.12 (1.05, 4.29)
Adjustment model 2 25 3.68 (1.04, 13.00) 18 3.17 (0.82, 12.3) 43 2.44 (1.12, 5.31)
Adjustment model 3 25 2.88 (0.72, 11.60) 18 2.86 (0.69, 11.8) 43 2.27 (1.02, 5.08)
Adjustment model 1 controlled for stage (0/I, II, III, and IV), grade (I, II, and III/IV), hormone receptor status (ER+ or PR+, ER−, and PR−), and age (continuous). In addition to the 
variables in adjustment model 1, adjustment model 2 controlled for smoking (former and current versus never) and BMI (<25, 25–2.9, 30–34.9, and 35+). In addition to the variables 
in adjustment model 2, adjustment model 3 controlled for payer type (private, Medicare, or Uniform, and None or Medicaid), receipt of chemotherapy, and receipt of radiation therapy.
TaBle 3 | comparison of host and tumor characteristics between 
patients with high nlr (≥3.7) versus low nlr (<3.7) in a hospital-based 
retrospective cohort study (2001–2013).
nlr <3.7 nlr ≥3.7 p-Value
Total no. 409 52
Median ± iQr
White blood cells 6.60 ± 2.70 7.75 ± 3.42 <0.0001
Neutrophils 3.78 ± 2.06 5.82 ± 2.82 <0.0001
Lymphocytes 2.08 ± 0.80 1.22 ± 0.666 <0.0001
Monocytes 0.47 ± 0.23 0.48 ± 0.32 0.75
Age 57.60 ± 19.40 57.40 ± 15.30 0.819
BMI 29.70 ± 9.49 27.5 ± 9.72 0.819
no. (%)
race 0.071
Black 216 (52.8) 20 (38.5)
White 193 (47.2) 32 (61.5)
stage 0.198
I 192 (50.7) 20 (41.7)
II 104 (27.4) 12 (25.0)
III 53 (14.0) 8 (16.7)
IV 30 (7.9) 8 (16.7)
grade 0.1
I 78 (22.3) 6 (14.3)
II 107 (30.6) 8 (19.0)
III/IV 165 (47.1) 28 (66.7)
smoking 0.85
Never 227 (61.5) 27 (57.4)
Former 68 (18.4) 10 (21.3)
Current 74 (20.1) 10 (21.3)
Payer 0.833
Private/Medicare/uniformed 301 (74.5) 36 (72.0)
Medicaid/none 103 (25.5) 14 (28.0)
p-Values were obtained using Pearson’s chi-squared tests for categorical variables with 
simulated p-values used when necessary and the Mann–Whitney test for continuous 
variables.
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reported in studies based on triple-negative breast cancer patients 
(19, 39). In a population of 187 HER2-positive breast cancer 
patients treated with adjuvant trastuzumab in medical centers in 
Turkey, Ulas et al. reported that patients with a pretreatment NLR 
>2.38 had shorter disease-free survival, but their findings were 
non-significant (p = 0.45) (40).
Several studies also point to the association of pretreatment 
NLR with overall survival in breast cancer patients. A meta-analy-
sis of five studies published in 2014 has summarized that elevated 
pretreatment NLR, with the cutoff values ranged between 2.0 and 
4.0, was associated with a significant increase in all-cause mortality 
(HR = 2.3, 95% CI: 1.1–4.8) but to a lesser extent with disease-free 
survival (HR = 1.4, 95% CI: 0.9–2.1) (17). Subgroup analyses also 
indicated that the significant association between pretreatment 
NLR and prognostic utility of NLR is more evident among White 
versus Asian patients (17). Consistent with this notion, a recent 
large study based on patients of different Asian ethnic groups 
reported a significant, but modest, association between high 
pretreatment NLR and overall death among breast cancer patients 
(18). However, to the best of our knowledge, there has been no 
research that included adequate number of Black patients.
Black individuals have lower WBC and absolute neutrophil 
counts compared with White individuals (32) primarily due to 
genetic deletion of the Duffy antigen receptor for chemokines 
that has been hypothesized to affect the number of circulating 
neutrophils (41, 42). Consistent with this understanding, Black 
patients in our dataset had lower NLR values than White patients, 
even after stratifying patients by tumor stage. This trend led us 
to determine different optimal NLR cutoff points for Black and 
White patients separately. Reflecting an overall lower NLR value 
in Black patients, a slightly lower NLR cutoff was selected for 
Black patients compared with White patients, but the difference 
was not large enough to warrant race-specific cutoff points. We 
also found that the association between pretreatment NLR value 
and tumor stage was less evident among Black patients. However, 
the association between NLR and all-cause and breast cancer-
specific mortality remained similar with comparable estimates 
using either race-specific or a unified cutoff point value, and there 
was no evidence suggesting racial heterogeneity of the prognostic 
utility of NLR.
Inflammation and host immune response can be a critical 
factor for breast cancer prognosis by altering the tumor micro-
environment and therapeutic efficacy (43). Peripheral immune 
TaBle 5 | Breast cancer-specific mortality in relation to high nlr (≥3.7) versus low nlr (<3.7).
Black White combined
Deaths hr 95% ci Deaths hr 95% ci Deaths hr 95% ci
all stages
Unadjusted 33 2.47 (0.95, 6.39) 21 2.15 (0.79, 5.86) 54 2.16 (1.09, 4.3)
Adjustment model 1 24 1.08 (0.30, 3.94) 10 1.41 (0.25, 7.96) 34 1.78 (0.71, 4.42)
Adjustment model 2 22 0.57 (0.12, 2.73) 8 4.74 (0.23, 99.30) 30 1.27 (0.46, 3.45)
Adjustment model 3 22 0.59 (0.10, 3.45) 8 a a 30 1.46 (0.46, 4.62)
excluding stage iV
Unadjusted 17 3.31 (0.95, 11.60) 6 1.51 (0.18, 12.90) 23 2.22 (0.75, 6.53)
Adjustment model 1 16 2.73 (0.75, 10.00) 3 a a 19 2.71 (0.86, 8.56)
Adjustment model 2 14 1.40 (0.26, 7.51) 2 a a 16 1.52 (0.40, 5.85)
Adjustment model 3 14 1.06 (0.16, 7.16) 2 a a 16 1.69 (0.38, 7.55)
aModel did not converge. Adjustment model 1 controlled for stage (0/I, II, III, and IV), grade (I, II, and III/IV), hormone receptor status (ER+ or PR+, ER−, and PR−), and age 
(continuous). In addition to the variables in adjustment model 1, adjustment model 2 controlled for smoking (former and current versus never) and BMI (<25, 25–2.9, 30–34.9, 
and 35+). In addition to the variables in adjustment model 2, adjustment model 3 controlled for payer type (private, Medicare, or Uniform, and None or Medicaid), receipt of 
chemotherapy, and receipt of radiation therapy.
FigUre 3 | Overall survival by high nlr (≥3.7) versus low nlr (<3.7) among Black and White breast cancer patients. p-Values are for the log-rank test.
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parameters, such as NLR studied in the present study, are a plau-
sible and practically attractive marker of systemic inflammatory 
responses (44) and may reflect tumor-specific immune response. 
In a recent study of non-small cell lung cancer patients, the high 
NLR was correlated with TILs and independently associated 
with the prognosis (45). However, NLR largely represents a non- 
specific indicator of an immune state (46). For example, an ele-
vated NLR has been linked to worse outcomes in various diseases 
across several different cancer types and those outside of cancer, 
including coronary artery disease and heart failure (47–49). In a 
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large cohort study that included both patients with and without 
cancer, high neutrophil and low lymphocyte counts were associ-
ated with an increase in all-cause mortality and cardiovascular 
mortality as well as cancer-specific mortality (48). It is known 
that women, especially elderly women, diagnosed with early stage 
breast cancers are more likely to die because of cardiovascular 
diseases than from breast cancer (50). We were unable to estimate 
cardiovascular disease-specific mortality or its contribution to 
the observed association between NLR and all-cause mortality 
in our cohort. However, these findings, including our study, 
emphasize the pervasive effect that inflammation has on several 
aspects of health in several different organ systems and processes. 
It should be also noted that although this study focused on NLR, 
the prognostic implication of inflammation could not be fully 
captured, using this single marker of inflammation. However, 
combined with other markers of local and systemic inflamma-
tion, NLR, a low-cost, reliable marker of inflammation may have 
potential utility in predicting short- and long-term prognosis and 
risk stratification for anti-inflammatory or immune therapy for 
cancer patients in the future.
Several strengths and limitations exist within the study. In 
terms of strengths, this study is one of the first to determine the 
association of pretreatment NLR to both all-cause and breast 
cancer-specific mortality in a group of Black and White patients. 
Nearly, equal numbers of Black and White patients were included, 
allowing us to explore a meaningful cutoff point in both racial 
groups. We used a cutoff point determination method for survival 
analysis to select a cutoff point that maximizes the relation with 
the HRs and SEs in Black and White patients (33, 34). Because the 
distribution of NLR varies in the two racial groups and the bio-
logical meaning in terms of breast cancer prognosis is unknown, 
we believe this method was well suited to the nature of our data 
and the specific purpose of our study to examine the associa-
tion between NLR and prognosis in Black and White patients. 
However, the prognostic value of our chosen cutoff point can be 
only determined after validation in independent datasets.
In terms of weaknesses, our study relied on medical records 
to identify breast cancer-specific death based on a priori criteria. 
Our data had comparable numbers of breast cancer-specific 
deaths by stage to those reported in a previous national death 
registry-based study (51), but some unquantifiable level of clas-
sification bias is unavoidable. The nature of a retrospective chart 
review created additional limitations to our study. First, while we 
began with a cohort of 461 patients, we lost several patients in 
subsequent models adjusting for potential confounding factors 
due to incomplete patient records. Thus, while the adjustment 
models became subsequently more specific in their analysis, they 
may have lost statistical significance due to decreasing numbers 
of patients included in the model. Second, we lacked patient data 
on cardiometabolic health status and cardiovascular health risk 
factors. As NLR has been previously shown to be associated with 
increased prevalence of coronary artery disease and cardiovas-
cular mortality (48, 49, 52–55), the relationship between NLR 
and cardiometabolic status in our patient cohort could have 
further weakened the specificity of NLR for breast cancer-specific 
mortality. Finally, the present study conducted subgroup analyses 
by race and metastasis status at diagnosis. Although the analyses 
were planned and guided by biological plausibility, the resulting 
increased number of testing will raise the probability of false 
positive findings.
The results of the present retrospective cohort of 461 Black 
and White breast cancer patients showed that elevated NLR 
defined as an NLR of 3.7 or higher is an independent predictor 
of all-cause mortality in non-metastatic breast cancer patients. 
Further studies, preferably in a patient population with available 
cardiovascular health data, are needed to clarify the appropriate 
clinical context to use NLR as a prognostic factor.
aUThOr cOnTriBUTiOns
JR, JC, JK, S-CT, and SK designed the study presented in this 
manuscript. JR and SK collected data from the electronic health 
records for this study. JC and JK performed the statistical analyses 
for this study. JR, JC, and SK wrote the manuscript and created the 
tables and figures with input from JK and S-CT.
FUnDing
This work was supported by Georgia Regents University Research 
Start-Up Fund.
reFerences
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 
65(1):5–29. doi:10.3322/caac.21254 
2. American Joint Committee on Cancer. AJCC Cancer Staging Handbook: From 
the AJCC Cancer Staging Manual. New York: Springer (2002).
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The 
value of histological grade in breast cancer: experience from a large study 
with long-term follow-up. Histopathology (1991) 41(3a):403–10. doi:10.111
1/j.1365-2559.1991.tb00229.x 
4. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estro-
gen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 
46(S12):2884–8. doi:10.1002/1097-0142(19801215)46:12+<2884::AID- 
CNCR2820461429>3.0.CO;2-U 
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 
Human breast cancer: correlation of relapse and survival with amplification 
of the HER-2/neu oncogene. Science (1987) 235(21):0–5. doi:10.1126/
science.3798106 
6. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes 
WD. Prognostic significance of CD8+ T lymphocytes in breast cancer 
depends upon both oestrogen receptor status and histological grade. 
Histopathology (2011) 58(7):1107–16. doi:10.1111/j.1365-2559.2011. 
03846.x 
7. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association 
between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. 
Ann Oncol (2014) 25(8):1536–43. doi:10.1093/annonc/mdu191 
8. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment 
levels of plasma C-reactive protein are associated with poor prognosis after 
breast cancer: a cohort study. Breast Cancer Res (2011) 13(3):R55. doi:10.1186/
bcr2891 
9. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: 
mechanisms of action and potential targets for therapeutics. Curr Drug Targets 
(2010) 11(9):1133–46. doi:10.2174/138945010792006799 
10. Wang S, Zhang Z, Fang F, Gao X, Sun W, Liu H. The neutrophil/lymphocyte 
ratio is an independent prognostic indicator in patients with bone metastasis. 
Oncol Lett (2011) 2:735–40. doi:10.3892/ol.2011.304 
9Rimando et al. Neutrophil–Lymphocyte Ratio in Breast Cancer
Frontiers in Oncology | www.frontiersin.org March 2016 | Volume 6 | Article 81
11. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et  al. 
Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and 
long-term mortality in breast cancer patients. Ann Surg Oncol (2012) 
19(1):217–24. doi:10.1245/s10434-011-1814-0 
12. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et  al. Pretreatment 
neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a 
predictor of long-term mortality in breast cancer patients. Med Oncol (2013) 
30(1):432. doi:10.1007/s12032-012-0432-4 
13. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lympho-
cyte ratio in predicting disease-specific survival in breast cancer patients. 
J Breast Cancer (2013) 16(1):55–9. doi:10.4048/jbc.2013.16.1.55 
14. Nakano K, Hosoda M, Yamamoto M, Yamashita H. Prognostic significance of 
pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast 
cancer. Anticancer Res (2014) 34:3819–24. 
15. Forget P, Machiels J-P, Coulie PG, Berliere M, Poncelet AJ, Tombal B, et al. 
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac 
are prognostic factors in different cohorts of patients undergoing breast, lung, 
and kidney cancer surgery. Ann Surg Oncol (2013) 20(Suppl 3):S650–60. 
doi:10.1245/s10434-013-3136-x 
16. Eryilmaz MK, Mutlu H, Salim DK, Yalcin F, Tural D, Coskun HS. The neu-
trophil to lymphocyte ratio has a high negative predictive value for pathologic 
complete response in locally advanced breast cancer patients receiving 
neoadjuvant chemotherapy. Asian Pac J Cancer Prev (2014) 15:7737–40. 
doi:10.7314/APJCP.2014.15.18.7737 
17. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neu-
trophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio (2015) 5:502–7. 
doi:10.1016/j.fob.2015.05.003 
18. Koh C-H, Bhoo-Pathy N, Ng K-L, Jabir RS, Tan G-H, See M-H, et al. Utility 
of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio 
as prognostic factors in breast cancer. Br J Cancer (2015) 113(1):150–8. 
doi:10.1038/bjc.2015.183 
19. Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, 
et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in 
predicting survival in early triple negative breast cancer patients. BMC Cancer 
(2015) 15(1):195. doi:10.1186/s12885-015-1204-2 
20. Kaneko M, Nozawa H, Sasaki K, Hongo K, Hiyoshi M, Tada N, et al. Elevated 
neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal 
cancer patients receiving oxaliplatin-based chemotherapy. Oncology (2012) 
82(5):261–8. doi:10.1159/000337228 
21. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. 
Neutrophil/lymphocyte ratio and its association with survival after complete 
resection in non-small cell lung cancer. J Thorac Cardiovasc Surg (2009) 
137(2):425–8. doi:10.1016/j.jtcvs.2008.05.046 
22. Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, et al. 
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in 
stage IV non-small cell lung cancer. Clin Transl Oncol (2012) 14(11):864–9. 
doi:10.1007/s12094-012-0872-5 
23. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment 
neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in 
patients with nonmetastatic renal cell carcinoma. J Urol (2010) 184(3):873–8. 
doi:10.1016/j.juro.2010.05.028 
24. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, 
et al. The association of pre-treatment neutrophil to lymphocyte ratio with 
response rate, progression free survival and overall survival of patients 
treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2012) 
48(2):202–8. doi:10.1016/j.ejca.2011.09.001 
25. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High 
preoperative neutrophil-lymphocyte ratio predicts poor survival in patients 
with gastric cancer. Gastric Cancer (2010) 13(3):170–6. doi:10.1007/
s10120-010-0554-3 
26. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, et al. Elevated preoper-
ative neutrophil to lymphocyte ratio predicts poor survival following resection 
in late stage gastric cancer. J Surg Oncol (2011) 104(5):504–10. doi:10.1002/
jso.21986 
27. An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lympho-
cyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 
(2011) 32(2):317–24. doi:10.1007/s13277-010-0124-7 
28. He J, Shen G, Ren A, Qin H, Cui C, Zhang Y, et  al. Pretreatment levels of 
peripheral neutrophils and lymphocytes as independent prognostic factors in 
patients with nasopharyngeal carcinoma. Head Neck (2012) 34(12):1769–76. 
doi:10.1002/hed.22008 
29. Gomez D, Farid S, Malik HZ, Young L, Toogood GJ, Lodge JP, et al. Preoperative 
neutrophil-to-lymphocyte ratio as a prognostic predictor after curative 
resection for hepatocellular carcinoma. World J Surg (2008) 32(8):1757–62. 
doi:10.1007/s00268-008-9552-6 
30. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated 
preoperative neutrophil: lymphocyte ratio as a predictor of postoperative dis-
ease recurrence in esophageal cancer. Ann Surg Oncol (2011) 18(12):3362–9. 
doi:10.1245/s10434-011-1754-8 
31. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio 
predicts chemotherapy outcomes in patients with advanced colorectal cancer. 
Br J Cancer (2011) 104(8):1288–95. doi:10.1038/bjc.2011.100 
32. Hsieh M, Everhart J, Byrd-Holt D, Tisdale J, Rodgers G. Prevalence 
of neutrophenia in the U.S. population: age, sex, smoking status, 
and ethnic differences. Ann Intern Med (2007) 146(7):486–92. 
doi:10.7326/0003-4819-146-7-200704030-00004 
33. Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods 
in survival analysis using SAS. Proceedings of the 28th SAS Users Group 
International Conference (SUGI). Seattle (2003).
34. Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, 
et al. The role of relative lymphocyte count as a biomarker for the effect of 
catumaxomab on survival in malignant ascites patients: results from a phase 
II/III study. Clin Cancer Res (2014) 20(12):3348–57. doi:10.1158/1078-0432.
CCR-13-2351 
35. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 
420(6917):860–7. doi:10.1038/nature01322 
36. Joyce J, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev 
Cancer (2009) 9(4):239–52. doi:10.1038/nrc2618 
37. Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp K, 
et al. The elevated preoperative derived neutrophil-to-lymphocyte ratio pre-
dicts poor clinical outcome in breast cancer patients. Tumour Biol (2015):1–8. 
doi:10.1007/s13277-015-3805-4 
38. Grenader T, Plotkin Y, Geffen DB. The preoperative neutrophil/lymphocyte 
ratio does not correlate with the 21-gene recurrence score in estrogen 
receptor-positive breast cancer patients. Oncol Res Treat (2015) 38(1–2):24–7. 
doi:10.1159/000370341 
39. Hong J, Mao Y, Chen X, Zhu L, He J, Chen W, et al. Elevated preoperative 
neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese 
women with breast cancer. Tumour Biol (2015). 
40. Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Degirmenci M. Are neutrophil/
lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in 
patients with HER2- positive early breast cancer receiving adjuvant trastu-
zumab? J BUON (2015) 20(3):714–22. 
41. Bonecchi R, Borroni EM, Savino B, Buracchi C, Mantovani A, Locati 
M. Non-signaling chemokine receptors: mechanism of action and 
role in  vivo. J Neuroimmunol (2008) 198(1–2):14–9. doi:10.1016/j.
jneuroim.2008.04.018 
42. Reich D, Nalls MA, Kao WHL, Akylbekova EL, Tandon A, Patterson N, et al. 
Reduced neutrophil count in people of African descent is due to a regulatory 
variant in the Duffy antigen receptor for chemokines gene. PLoS Genet (2009) 
5(1):e1000360. doi:10.1371/journal.pgen.1000360 
43. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. 
Mol Cell Endocrinol (2014) 382(1):673–82. doi:10.1016/j.mce.2013.06.003 
44. Characiejus D, Jacobs JJL, Pašukonienė V, Kazlauskaitė N, Danilevičiūtė 
V, Mauricas M, et  al. Prediction of response in cancer immunotherapy. 
Anticancer Res (2011) 31(2):639–47. 
45. Dirican N, Karakaya Y, Gunes S, Daloglu F, Dirican A. Association of intratu-
moral tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio are 
an independent prognostic factor in non-small cell lung cancer. Clin Respir J 
(2015). doi:10.1111/crj.12417 
46. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do 
they mirror the situation in all organs? Immunol Lett (2007) 108(1):45–51. 
doi:10.1016/j.imlet.2006.10.009 
47. Ross R. Inflammation or atherogenesis. N Engl J Med (1999) 340(2):115–26. 
48. Proctor MJ, McMillan DC, Horgan PG, Fletcher CD, Talwar D, Morrison DS. 
Systemic inflammation predicts all-cause mortality: a Glasgow Inflammation 
Outcome Study. PLoS One (2015) 10(3):e0116206. doi:10.1371/journal.
pone.0116206 
10
Rimando et al. Neutrophil–Lymphocyte Ratio in Breast Cancer
Frontiers in Oncology | www.frontiersin.org March 2016 | Volume 6 | Article 81
49. Verdoia M, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca 
G, et  al. Neutrophil to lymphocyte ratio and the extent of coronary artery 
disease: results from a large cohort study. Angiology (2016) 67(1):75–82. 
doi:10.1177/0003319715577529 
50. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. 
Cardiovascular disease competes with breast cancer as the leading 
cause of death for older females diagnosed with breast cancer: a 
retrospective cohort study. Breast Cancer Res (2011) 13(3):R64. 
doi:10.1186/bcr2901 
51. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast 
cancer and other causes among female breast cancer patients. J Natl Cancer 
Inst (2004) 96(17):1311–21. doi:10.1093/jnci/djh253 
52. Núñez J, Núñez E, Bodí V, Sanchis J, Miñana G, Mainar L, et al. Usefulness 
of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST 
segment elevation myocardial infarction. Am J Cardiol (2008) 101(6):747–52. 
doi:10.1016/j.amjcard.2007.11.004 
53. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. 
Association between admission neutrophil to lymphocyte ratio and outcomes 
in patients with acute coronary syndrome. Am J Cardiol (2008) 102(6):653–7. 
doi:10.1016/j.amjcard.2008.05.006 
54. Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, et  al. 
Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-
term mortality after non-ST-elevation myocardial infarction. Am J Cardiol 
(2010) 106(4):470–6. doi:10.1016/j.amjcard.2010.03.062 
55. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley 
M, et  al. Utility of the neutrophil to lymphocyte ratio in predicting long-
term outcomes in acute decompensated heart failure. Am J Cardiol (2011) 
107(3):433–8. doi:10.1016/j.amjcard.2010.09.039 
Conflict of Interest Statement: The authors declare that this research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Rimando, Campbell, Kim, Tang and Kim. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
